Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Work
Year: 2015
Type: article
Abstract: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are rec... more
Source: New England Journal of Medicine
Institutions University of Iowa, Center Point, Hôpital Nord, Centre Hospitalier Universitaire de Nantes, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo +9 more
Cites: 35
Cited by: 2,146
Related to: 10
FWCI: 347.4
Citation percentile (by year/subfield): 100
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze